Inhaled drug aims to save transplanted lungs from silent threat
NCT ID NCT04039347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inhaled form of cyclosporine A (L-CsA) added to standard care for lung transplant patients with bronchiolitis obliterans syndrome (BOS), a condition that scars the lungs' small airways. The goal was to see if the treatment could slow the decline in lung function over 24 to 48 weeks. The trial included 164 patients who had already completed earlier studies, but it was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Banner - University Medical Center
Phoenix, Arizona, 85006, United States
-
Barnes-Jewish Hospital
St Louis, Missouri, 63110, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
CHU Hopital Nord
Marseille, France
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Complexo Hospitalario de A Coruna
A Coruña, Spain
-
Copenhagen University Hospital
Copenhagen, Denmark
-
David Geffen School of Medicine at UCLA
Los Angeles, California, 90095, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Hannover Medical School
Hanover, Germany
-
Hopital Marie Lannelongue
Le Plessis-Robinson, 92350, France
-
Hopitaux Universitaires de Strasbourg
Strasbourg, France
-
Hospital Marques de Valdecilla
Santander, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Puerta de Hierro - Unidad de Trasplante Pulmonar
Madrid, 28222, Spain
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Hôpital Erasme
Brussels, 1070, Belgium
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University Hospital
Baltimore, Maryland, 21287, United States
-
LMU Klinikum Groshadern
Munich, Germany
-
OSU Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Rabin Medical Center
Petah Tikva, Israel
-
Royal Papworth Hospital NHS Foundation Trust
Cambridge, CB23 3RE, United Kingdom
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
UCSF
San Francisco, California, 94143, United States
-
UCSF Center for Advanced Lung Disease
Stanford, California, 94305, United States
-
UK Albert B. Chandler Hospital
Lexington, Kentucky, 40508, United States
-
Unidad de Trasplante Pulmonar del Hospital La Fe
Valencia, 46026, Spain
-
Universitair Ziekenhuis Leuven
Leuven, 3000, Belgium
-
University of Florida Dept of Pulmonary Medicine
Gainesville, Florida, 32610, United States
-
University of Manchester
Manchester, United Kingdom
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Waehringer Guertel
Vienna, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can airway cell clues predict a rare lung disease in children?
- New study aims to detect lung damage earlier in young transplant patients
- Can lung MRI replace CT scans for detecting a serious Post-Transplant lung condition?
- New inhaled therapy aims to slow lung transplant rejection
- New xenon MRI could spot lung damage in kids after transplant
- New hope for lung scarring after transplant: belumosudil trial launches